Published in Hum Vaccin Immunother on September 20, 2012
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res (2015) 1.80
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res (2013) 1.16
Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines (2014) 0.86
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl (2014) 0.84
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget (2016) 0.79
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. Oncoimmunology (2015) 0.78
Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma. Immunol Lett (2015) 0.75
Opportunities in immunotherapy of ovarian cancer. Ann Oncol (2016) 0.75
Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. Hum Vaccin Immunother (2016) 0.75
Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother (2014) 0.75
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8(+) and CD4(+) T cells. Immunology (2017) 0.75
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. J Natl Cancer Inst (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Cancer vaccines: moving beyond current paradigms. Clin Cancer Res (2007) 2.40
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res (2007) 2.38
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol (2009) 2.04
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res (2005) 1.49
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm (2012) 1.16
Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol (2011) 1.15
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother (2011) 0.97
High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. J Immunother (2009) 0.91
Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci (2010) 0.85
Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients. Immunotherapy (2011) 0.85
Cancer vaccines: should we be targeting patients with less aggressive disease? Expert Rev Vaccines (2012) 0.82